1.. Introduction   {#sec1}
==================

The concept of supramolecular synthons introduced by Desiraju in 1995 (Desiraju, 1995[@bb21]; Thalladi *et al.*, 1996[@bb75]; Reddy *et al.*, 1996[@bb64]; Dunitz & Gavezzotti, 2012[@bb25]; Nangia & Desiraju, 1998[@bb60]) led to the identification of known and new hydrogen bond patterns in crystal engineering. Zaworotko and coworkers (Walsh *et al.*, 2003[@bb87]) sub-classified synthons as homosynthons (those between like functional groups) and heterosynthons (hydrogen bonds between unlike groups). The past decade has witnessed immense interest in utilizing various supramolecular synthons to direct structural organization in the crystal structure. For example, acid--acid and amide--amide homosynthons are well known, while acid--pyridine and acid--amide are popular heterosynthons. The latter form of association between unlike functional groups has immediate potential in the engineering of multi-component systems, notably cocrystals (Vishweshwar *et al.*, 2003*a* [@bb85],*b* [@bb86]; Biradha & Zaworotko, 1998[@bb7]; Bis & Zaworotko, 2005[@bb9]; Bis *et al.*, 2006[@bb8]; Vangala *et al.*, 2005[@bb84]; Ermer & Eling, 1994[@bb27]; Reddy *et al.*, 2006[@bb62], 2007[@bb63]; Babu *et al.*, 2007[@bb4]; Goud *et al.*, 2011[@bb43]; Kaur & Guru Row, 2012[@bb48])

Selected homo- and heterosynthons extracted from the literature for single and multi-component systems of sulfonamides are listed in Fig. 1[▸](#fig1){ref-type="fig"}. The directionality and strength of hydrogen bonding plays a major role in controlling the supramolecular assembly through complementary functional groups, which leads to the application of crystal engineering in material science and pharmaceutical solids (Childs *et al.*, 2004[@bb13]; Trask, Motherwell & Jones, 2004[@bb78], 2005[@bb79], 2006[@bb80]; Trask, Haynes *et al.*, 2006[@bb76]). The pairing of best-donor to best-acceptor hydrogen bonding (Etter's rules) guides cocrystal design in a majority of cases (Etter, 1982[@bb28], 1990[@bb29], 1991[@bb31]). However, as multiple functional groups come into interplay, the competition can be more complex and difficult to predict (Sarma *et al.*, 2009[@bb69]; Aakeröy *et al.*, 2013[@bb1]). For this reason, we examined heterosynthons of sulfonamides with the amide group in non-competing binary systems with the idea of developing a library of sulfonamide--carboxamide synthons. Whereas sulfonamide and carboxamide homosynthons have been studied, this is a report on their heterosynthons. Sulfon­amides preferably form dimer and catemer synthons, whereas carboxamides more often assemble *via* the dimer synthon (Sanphui *et al.*, 2010[@bb68]). A robust heterosynthon for sulfonamide group cocrystals is that with pyridine *N*-oxides (Goud *et al.*, 2011[@bb43]), but since the latter coformers are not pharmaceutically acceptable, there is a need to develop a design strategy for sulfonamides with GRAS amides (US-FDA, 2014[@bb82]). Selected data on sulfonamides were extracted from the Cambridge Structural Database (CSD, Version 5.36, November 2014 release). With this background, benzene sulfonamides were cocrystallized with cyclic carboxamides to analyze isostructural relationships and classify the observed synthons.

Primary sulfonamides attached to a substituted phenyl ring were selected in this exploratory cocrystal study to identify the basic heterosynthons with amides in a non-competitive environment. We were successful in obtaining cocrystals of a few benzene sulfonamides with lactams (*syn* amides) listed in Fig. 2[▸](#fig2){ref-type="fig"}. A reason to choose cyclic amides over primary amides was that the latter have *syn* and *anti* N---H donors, and together with primary sulfonamide, which also has *syn* and *anti* N---H donors, the diversity of hydrogen bond motifs may become too complex for systematic analysis. In a recent study of lactams with carboxylic acids, Moragues-Bartolome *et al.* (2012[@bb57]) found that 2-pyrrolidone showed a heterotetramer (CONH⋯COOH), whereas δ-valerolactam has a homotetramer synthon (CONH⋯CONH), although there were some mixed results as well (Moragues-Bartolome *et al.*, 2012[@bb57]). We report in this paper isostructural pairs of cocrystals (sulfonamide--lactam) having isosynthons (similar supramolecular synthons). The lattice parameters and crystal packing of the X-ray crystal structures suggest that there are three sets of isostructural compounds and that each set has its own isosynthons. Primary sulfonamides consist of two acceptor O atoms and two donor H atoms (SO~2~NH~2~), and the complementary functional group lactam (HN---C=O) also has one donor and one acceptor.

2.. Experimental   {#sec2}
==================

2.1.. Preparation of cocrystals   {#sec2.1}
---------------------------------

All the benzene sulfonamides and coformers (caprolactam, valerolactam *etc.*) used in this study (see Fig. 2[▸](#fig2){ref-type="fig"}) were purchased from Sigma--Aldrich, Hyderabad, India, and used as such without further purification. Equivalent amounts of the sulfonamide and coformer were taken in a mortar and ground with a pestle for 20--30 min using solvent-assisted grinding by adding a few drops of EtOAc. After confirming that the ground mixture is a new solid phase by powder X-ray diffraction (PXRD), the mixture was dissolved in EtOAc or EtOAc--THF. The solution was then allowed to cocrystallize at room temperature by slow evaporation. Suitable crystals for single-crystal X-ray data were obtained after 5--6 d. A summary of the grinding experiments, characterizations of cocrystals by PXRD and IR, and confirmation by single-crystal X-ray diffraction (SC-XRD) are listed in Table 1[▸](#table1){ref-type="table"}.

2.2.. BSA--VLM cocrystal (1:1)   {#sec2.2}
--------------------------------

BSA (100 mg, 0.636 mmol) and VLM (63 mg, 0.636 mmol) were ground well in a mortar and pestle for 20--30 min by adding 4--7 drops of EtOAc (liquid-assisted grinding or LAG; Shan *et al.*, 2002[@bb72]; Trask & Jones, 2005[@bb77]; Friščić *et al.*, 2006[@bb39]). The ground material was kept for crystallization in 5 ml of an EtOAc--THF mixture as well as in individual solvents at room temperature. Good diffraction-quality crystals were harvested under ambient conditions after 3--4 d; m.p. 79--81°C.

2.3.. BSA--CPR cocrystal (1:1)   {#sec2.3}
--------------------------------

BSA (100 mg, 0.636 mmol) and CPR (72 mg, 0.636 mmol) were ground well in a mortar and pestle for 20--30 min by adding 4--7 drops of EtOAc. The ground material was kept for crystallization in 5 mL of an EtOAc--THF solvent mixture as well as in individual solvents in a 25 ml conical flask at room temperature. Good quality crystals were harvested under ambient conditions after 3--4 days; m.p. 80--83°C.

2.4.. BSA--AZL (1-aza-2-cyclooctanone) cocrystal (1:1)   {#sec2.4}
--------------------------------------------------------

BSA (100 mg, 0.636 mmol) and AZL (80.87 mg, 0.636 mmol) were ground well in a mortar and pestle for 20--30 min by adding 4--7 drops of EtOAc. The ground material was kept for crystallization in 5 mL of an EtOAc--THF mixture as well as individual solvents in a 25 ml conical flask at room temperature. Good quality crystals were harvested under ambient conditions after 3--4 days; m.p. 76--81°C.

2.5.. 2ClBSA--VLM, 4ClBSA--VLM cocrystal (1:1)   {#sec2.5}
------------------------------------------------

ClBSA isomer (100 mg, 0.521 mmol) and VLM (51.6 mg, 0.521 mmol) were ground well in a mortar and pestle for 20--30 min by adding 5 drops of EtOAc. The ground material was kept for crystallization in 5 mL of an EtOAc--THF mixture as well as individual solvents at room temperature. Single crystals were harvested under ambient conditions after 3--4 d; m.p. 80--82°C; 90--91°C

2.6.. 2ClBSA--CPR, 4ClBSA--CPR cocrystal (1:1)   {#sec2.6}
------------------------------------------------

ClBSA isomer (100 mg, 0.521 mmol) and CPR (59 mg, 0.521 mmol) were ground well in a mortar and pestle for 20--30 min by adding 5 drops of EtOAc. The ground material was kept for crystallization in 5 mL of an EtOAc--THF mixture, as well as separate solvents at room temperature. Single crystals were harvested under ambient conditions after 3--4 d; m.p. 80--82°C; 82--83°C.

2.7.. 4BrBSA--VLM cocrystal (1:1)   {#sec2.7}
-----------------------------------

4BrBSA (100 mg, 0.423 mmol) and VLM (51.6 mg, 0.423 mmol) were ground well in a mortar and pestle for 20--30 min with solvent assistance by adding 4--7 drops of EtOAc. The ground material was kept for crystallization in 5 mL of an EtOAc--THF mixture, as well as individual solvents at room temperature. Single crystals were harvested under ambient conditions after 3--4 d; m.p. 92--94°C.

2.8.. 4BrBSA--CPR cocrystal (1:1)   {#sec2.8}
-----------------------------------

4BrBSA (100 mg, 0.423 mmol) and CPR (58.95 mg, 0.423 mmol) were ground well in a mortar aand pestle for 20--30 min through solvent-assisted grinding by adding 5 drops of EtOAc. The ground material was kept for crystallization in 5 mL of EtOAc--THF mixture as well as separate solvents. Single crystals were harvested at ambient conditions after 3--4 days; m.p. 90--92°C.

2.9.. OTSA--VLM, PTSA--VLM cocrystal (1:1)   {#sec2.9}
--------------------------------------------

OTSA/PTSA (100 mg, 0.584 mmol) and VLM (57.89 mg, 0.584 mmol) were ground well in a mortar and pestle for 20--30 min through solvent-assisted grinding by adding 5 drops of EtOAc. The ground material was kept for crystallization in 5 mL of an EtOAc--THF mixture as well as separate solvents. Single crystals were harvested under ambient conditions after 3--4 days; m.p. 70--72°C; 74--75°C.

2.10.. SNA--VLM, 2ABSA--VLM cocrystal (1:1)   {#sec2.10}
---------------------------------------------

SNA/2ABSA (100 mg, 0.580 mmol) and VLM (65.63 mg, 0.580 mmol) were ground well in a mortar and pestle for 20--30 min through solvent-assisted grinding by adding 5 drops of EtOAc. The ground material was kept for crystallization in 5 mL of an EtOAc--THF mixture as well as separate solvents. Single crystals were harvested at ambient conditions after 3--4 d; m.p. 95--97°C, 87--91°C.

2.11.. Single-crystal X-ray diffraction   {#sec2.11}
-----------------------------------------

A single crystal obtained from the crystallization experiment was mounted on the goniometer of an Oxford Diffraction Gemini X-ray diffractometer equipped with an Mo *K*α radiation source (λ = 0.71073 Å). Data reduction was performed using *CrysAlisPro* 171.33.55 software. The crystal structure was solved and refined using Olex2-1.0 with anisotropic displacement parameters for non-H atoms. H atoms were experimentally located through the difference-Fourier electron density maps in all crystal structures. Data was reduced by *SAINT-Plus* (Bruker, 1998[@bb90]) and further continued with *SHELXTL* (Sheldrick, 2008[@bb91]). A check of the final crystallographic information file (CIF) with *PLATON* (Spek, 2009[@bb92]) did not show any missed symmetry. *X-Seed* was used to prepare the figures and packing diagrams. Crystallographic parameters of all the cocrystals are summarized in Table 2[▸](#table2){ref-type="table"}. Hydrogen bond distances (see Table S1 of the [supporting information](#suppinfoanchor)) are neutron-normalized (O---H 0.983, N---H 0.82, C---H 1.083 Å). CIF files are also deposited with the CCDC (Nos. 1039188--1039200).

Some single-crystal diffraction data were collected at 298 K on a Bruker SMART APEX-1 CCD area-detector system equipped with a graphite monochromator, Mo *K*α fine-focus sealed tube (λ = 0.71073 Å) operated at 1500 W power (40 kV, 30 mA). The frames were integrated with *SAINT* (Bruker, 1998[@bb90]) software using a narrow-frame integration algorithm. Data was corrected for absorption effects using the multi-scan method (*SADABS*; Bruker, 1998[@bb90]). The structure was solved and refined using *SHELXTL* (Sheldrick, 2008[@bb91]).

2.12.. X-ray powder diffraction   {#sec2.12}
---------------------------------

Bulk samples were analyzed by X-ray powder diffraction on a Bruker AXS D8 diffractometer (Bruker-AXS, Karlsruhe, Germany). Experimental conditions: Cu *K*α radiation (λ = 1.54056 Å); 40 kV; 30 mA; scanning interval 5--50° 2θ at a scan rate of 1° min^−1^; time per step 0.5 s. The experimental PXRD patterns of the BSA, 4Cl BSA and 4Br BSA cocrystals were compared to confirm the isostructurality (Fig. S4 of the [supporting information](#suppinfoanchor)).

2.13.. Vibrational spectroscopy   {#sec2.13}
---------------------------------

A Thermo-Nicolet 6700 FT--IR spectrometer (Waltham, MA, USA) was used to record the IR spectra. IR spectra were recorded on samples dispersed in KBr pellets. For details of IR spectra see [Fig. S8 and Table S4](#suppinfoanchor).

3.. Results and discussion   {#sec3}
============================

3.1.. Crystal structure analysis and isostructurality   {#sec3.1}
-------------------------------------------------------

A few benzene sulfonamides (listed in Fig. 2[▸](#fig2){ref-type="fig"}) were selected to make cocrystals with PYR, VLM, CPR and AZL cyclic amides in a 1:1 stoichiometric ratio, which were ground mechanochemically through solvent-assisted grinding to obtain cocrystals. The resulting binary systems were analyzed with greater emphasis on VLM and CPR cocrystals since they are pharmaceutically acceptable coformers. Three types of synthons were observed: synthon 1 or the catemer motif of graph-set *C* ~2~ ^1^(4) (Etter *et al.*, 1990[@bb32]; Bernstein *et al.*, 1995[@bb5]), synthon 2 which is a dimer--cyclic synthon motif of *R* ~2~ ^2^(8)*R* ~4~ ^2^(8), and synthon 3 as a dimer--catemer motif *R* ~2~ ^2^(8)*C* ~1~ ^1^(4)*D* (Fig. 3[▸](#fig3){ref-type="fig"}). The crystal structure of BSA with AZL contains synthon 2. The crystal structures of other primary sulfonamides with AZL, PYR *etc.* will be discussed separately. Cocrystals of celecoxib (SO~2~NH~2~ drug) with odd/even homolog cyclic amides (Bolla *et al.*, 2014[@bb10]) indicated that the odd ring size coformer (PYR, CPR) follows the heterosynthon, whereas even ring lactams (VLM, AZL) result in dimer--dimer/dimer--catemer synthons. With the aim of establishing a trend for sulfonamides, this study however did not give the previously observed synthons but resulted in different motifs. A robust and predictable functional group for sulfonamide cocrystals is pyridine *N*-oxide coformers (as well as P- and As-oxide) (*e.g.* Goud *et al.*, 2011[@bb43]; Croker *et al.*, 2012[@bb18]; Ferguson *et al.*, 1989[@bb37]; Denise *et al.*, 2014[@bb19]), but these are not of practical use as pharmaceuticals since they are not GRAS molecules (generally regarded as safe). The cocrystals obtained in this study and synthon classification are summarized in Fig. 3[▸](#fig3){ref-type="fig"}, along with crystallographic parameters in Table 2[▸](#table2){ref-type="table"} (additional data in Table 3[▸](#table3){ref-type="table"}).

3.2.. Synthon 1, catemer chain   {#sec3.2}
--------------------------------

Among the 13 cocrystal structures studied (Table 1[▸](#table1){ref-type="table"}), seven structures contain the sulfonamide--*syn*-carboxamide catemer synthon of *C* ~2~ ^1^(4) notation. The catemer chains are assembled by sulfonamide N---H donors hydrogen bonding to the carboxamide acceptor. The structures are isostructural upon altering the auxiliary functional groups of benzene sulfonamide, such as Cl/Br/NH~2~/CH~3~. BSA--VLM and BSA--CPR have the same unit-cell parameters, whereas *p*-substituted BSA molecules (such as 4ClBSA, 4BrBSA and SNA) showed a 0.5 Å increase in the crystallographic *b*- and *c*-axis. BSA--VLM, BSA--CPR, SNA--CPR, 4ClBSA--CPR and 4BrBSA--CPR are three-dimensional isostructural. There are two more sets of isostructural cocrystals, 4ClBSA--VLM and 4BrBSA--VLM, with the same synthon.

### 3.2.1.. BSA--VLM, BSA--CPR, SNA--CPR, 4 ClBSA--CPR and 4BrBSA--CPR (1:1)   {#sec3.2.1}

The crystal structures of all these multi-component systems were refined in the orthorhombic space group *P*2~1~2~1~2~1~. The sulfonamide NH~2~ donates an N---H⋯O hydrogen bond to both sides of the carbonyl group of the lactam acceptor in the synthon 1 catemer (Fig. 4[▸](#fig4){ref-type="fig"} *a*). The hydrogen-bonded *C*(4) chain runs along the *a*-axis and in a corrugated sheet-like structure parallel to the (011) plane (Fig. 4[▸](#fig4){ref-type="fig"}, [Fig. S1](#suppinfoanchor)) and exhibits three-dimensional isostructurality in crystal packing.

### 3.2.2.. ClBSA--VLM, 4BrBSA--VLM (1:1)   {#sec3.2.2}

These two cocrystals have the catemer synthon and furthermore there is diversity in the two-dimensional packing patterns compared with the above set of five cocrystals. Both these structures are of the synthon 1 category even though they have different two-dimensional packing. The initial growth unit is the catemer hydrogen bond chain in these crystal structures. Sulfonamides and carboxamides form catemer synthon chains parallel to the *b*-axis (space group *C*2/*c*), which results in successive chain motifs ([Fig. S1](#suppinfoanchor)). The two-dimensional sheet arrangements of these isostructural cases are displayed in Fig. 4[▸](#fig4){ref-type="fig"}.

3.3.. Synthon 2, dimer--cyclic ring   {#sec3.3}
-------------------------------------

### 3.3.1.. BSA--AZL cocrystal (1:1)   {#sec3.3.1}

The crystal structure was refined in the monoclinic space group *P*2~1~/*n*. Glide-related sulfonamide molecules are flanked between dimers of lactam through N---H⋯O (N1---H1*B*⋯O3: 2.12 Å, ∠158°; N1---H1*A*⋯O3: 2.03 Å, ∠158°) hydrogen bonds (sulfonamide NH donors) to give *R* ~2~ ^2^(8)*R* ~4~ ^2^(8) ring motif synthon 2 (Figs. 5[▸](#fig5){ref-type="fig"} *a* and *b*), similar to that in N-oxide cocrystals (Goud *et al.*, 2011[@bb43]). The structural units extend along the *a*-axis in a one-dimensional pattern. The *meta* H atoms of BSA form C---H⋯O interactions with S=O along the *a*-axis (Fig. 5[▸](#fig5){ref-type="fig"} *c*) resulting in corrugated layers of sulfonamide chains separated by coformer molecules ([Fig. S2](#suppinfoanchor)).

### 3.3.2.. ABSA--CPR cocrystal (1:1)   {#sec3.3.2}

This cocrystal is isostructural with BSA--AZL. The main synthon in 2ABSA--CPR is *R* ~2~ ^2^(8)*R* ~4~ ^2^(8) ring motifs along the *a*-axis (Fig. 5[▸](#fig5){ref-type="fig"} *d*) together with corrugated wave-like layers (Figs. 5[▸](#fig5){ref-type="fig"} *d* and *e*). The isostructurality is illustrated in [Fig. S2](#suppinfoanchor).

3.4.. Synthon 3, dimer--catemer   {#sec3.4}
---------------------------------

### 3.4.1.. ClBSA--VLM cocrystal (1:1)   {#sec3.4.1}

Equimolar quantities of the components were ground and crystallized from EtOAc to give single crystals which were solved in the monoclinic space group *P*2~1~/*c*. Catemer chains connect glide-related 2ClBSA molecules that assemble *via* homodimers of VLM through N---H⋯O (N1---H1*A*⋯O3 = 2.03 Å, ∠169°) hydrogen bonds in synthon 3, or dimer--catemer synthon *R* ~2~ ^2^(8)*C* ~1~ ^1^(4)*D* (Figs. 6[▸](#fig6){ref-type="fig"} *a* and *b*). In this synthon the coformer dimers are sandwiched between sulfonamide catemer chains. Halogen bonding (Cl⋯O, Cl⋯N) provides auxiliary support to the structure (Metrangolo *et al.*, 2005[@bb54], 2008[@bb53]; Saha & Nangia, 2007[@bb66]; Desiraju, 1989[@bb20]; Mukherjee *et al.*, 2014[@bb59]). The catemer chains of 2ClBSA extend along the *c*-axis and homodimers of VLM connect adjacent chains of sulfonamides *via* C---H⋯O interactions to make two-dimensional stacks in the *ab*-plane (Fig. 6[▸](#fig6){ref-type="fig"} *c*).

### 3.4.2.. ClBSA--CPR cocrystal (1:1)   {#sec3.4.2}

Cocrystal 2ClBSA--CPR is isostructural with 2ClBSA--VLM. Sulfonamide catemer chains are interlinked *via* discrete synthons to homodimers of CPR through N1---H1*A*⋯O3 hydrogen bonds (1.97 Å, ∠176°) to give synthon 3, dimer--catemer (Figs. 6[▸](#fig6){ref-type="fig"} *a* and *d*). The homodimers of CPR are sandwiched between chains of sulfonamide chains. These patterns grow *via* C---H⋯O interactions to make interestingly parachute-like cone rings (Fig. 6[▸](#fig6){ref-type="fig"} *e*).

### 3.4.3.. OTSA--VLM cocrystal (1:1)   {#sec3.4.3}

The OTSA molecule formed a cocrystal (monoclinic crystal system, *P*2~1~/*c* space group) with VLM homodimers (N2---H2*A*⋯O3 = 2.26 Å, ∠175°) *via* a discrete (*D* graph set) N---H⋯O (N1---H1*B*⋯O3 = 2.03 Å, ∠179°) synthon along the *c*-axis. Such dimers are sandwiched between screw-related sulfonamide chains, similar to two previous cocrystal structures (Fig. 6[▸](#fig6){ref-type="fig"} *f*). Supportive C---H⋯O interactions make parallel stacks (Fig. 6[▸](#fig6){ref-type="fig"} *g* and [Fig. S3*a*](#suppinfoanchor)).

### 3.4.4.. PTSA--VLM cocrystal (1:1)   {#sec3.4.4}

The crystal structure was solved in a triclinic crystal system with space group . The basic supramolecular synthon of the catemer type is also present in this cocrystal (Fig. 6[▸](#fig6){ref-type="fig"} *h*), but with different unit-cell parameters (Table 3[▸](#table3){ref-type="table"}). Sulfonamide molecules form catemer chain motifs above and below the VLM homodimers (N2---H2*A*⋯O3; H⋯O 2.15 Å, ∠176°; Fig. 6[▸](#fig6){ref-type="fig"} *i*). The sandwich-type structure is sustained by inversion-related sulfonamide chains in *AABB*-type stacking ([Fig. S3*b*](#suppinfoanchor)).

3.5.. Isostructural and isomorphous systems   {#sec3.5}
---------------------------------------------

Two crystals are said to be isostructural if they have the same structure, but not necessarily the same unit-cell dimensions nor the same chemical composition, with a comparable variability in the atomic coordinates to that of the cell dimensions and chemical composition (IUCr, 2014[@bb47]). Isostructurality depicts the arrangement of different molecules in a similar way in the crystal structure, but not necessarily their unit-cell parameters (Fábián, Argay & Kálmán, 1999[@bb34]; Fábián & Kálmán, 1999[@bb35], 2004[@bb36]; Kitaigorodsky, 1961[@bb49]). Certain substituents in the molecule can be replaced with others without altering the crystal packing as well as cell values and the space group (Brink & Kroese, 1952[@bb12]; Perutz, 1956[@bb61]; Kroon *et al.*, 1965[@bb51]; Sauer *et al.*, 1997[@bb70]; Dikundwar *et al.*, 2012[@bb23]). Such a functional group exchange leads to isostructural and isomorphous crystal structures (Berzelius, 1844[@bb6]; Melhado, 1980[@bb56]; Mitscherlich, 1822[@bb55]; Morrow, 1969[@bb58]). The recent literature on molecular cocrystals (Cinčić *et al.*, 2008*a* [@bb15],*b* [@bb16]; Dubey & Desiraju, 2014[@bb24]) and pharmaceutical multi-component systems, *e.g.* lamotrigine and olanzapine cocrystals and salts, provide examples of isostructurality (Ebenezer *et al.*, 2011[@bb26]; Galcera *et al.*, 2012[@bb40], 2013[@bb41]; Galcera & Molins, 2009[@bb42]; Clarke *et al.*, 2012[@bb17]; Thakuria & Nangia, 2013[@bb74]; Chitra *et al.*, 2012[@bb14]). The importance of isostructurality is that similar cocrystals can be designed depending on the geometry and shape and molecular composition of the starting materials. Isostructurality is also a useful guide in the crystal structure prediction of multi-component systems (Schmidt, 1971[@bb71]; Desiraju, 1989[@bb20]; Braga *et al.*, 1998[@bb11]; Desiraju *et al.*, 2011[@bb22]). Different guest molecules may be incorporated into the host lattice without substantially changing the crystal structure, *i.e.* isostructurality. The formation of isostructural cocrystals with the same synthon (isosynthon) and this study of sulfonamides with VLM, CPR shows how synthon similarity can lead to isostructural cocrystals (Fig. 3[▸](#fig3){ref-type="fig"}). There are four sets of isostructural cocrystals along with three types of synthons found in this set of cocrystals. Interestingly, a unique set of isostructural cocrystals shows isosynthons. Out of the 13 cocrystal structures in this study, four contain the dimer--catemer synthon, two result in the dimer--cyclic motif and seven gave the catemer synthon. Synthon 1 cocrystals exhibit two isostructural sets: set one of BSA--VLM, BSA--CPR, 4ClBSA--CPR, 4BrBSA--CPR, SNA--CPR and set two cocrystals 4ClBSA--CPR and 4BrBSA--CPR. These are three-dimensional isostructural systems and show isostructurality due to the Cl/Br/NH~2~ exchange (functional group) and VLM/CPR (homolog; Table 4[▸](#table4){ref-type="table"}). Further, the same trend continues for synthons 2 and 3 cocrystal sets also, *i.e.* isostructurality for Cl/Br and VLM/CPR. Furthermore, despite changes in molecular structures, the PXRD line patterns of synthon 1 cocrystals match quite well ([Fig. S4](#suppinfoanchor)) confirming their isomorphous nature.

Isostructurality was calculated on the basis of unit-cell parameters. Monoclinic and orthorhombic crystal structures show the unit-cell similarity index goes to zero (isostructurality) (see Table 2[▸](#table2){ref-type="table"})where *a*, *b*, *c* and *a*′, *b*′, *c*′ are orthogonalized lattice parameters of the related structures.

3.6.. Classification of sulfonamide synthons   {#sec3.6}
----------------------------------------------

A survey of the Cambridge Structural Database (CSD, Version 5.36, 1 November 2014[@bb82] update; Allen, 2002[@bb2]) furnished 220 hits of primary sulfonamides (after eliminating hydrates, solvates, salts and duplicates) and 2160 hits of secondary sulfonamides (Table 5[▸](#table5){ref-type="table"}). These reported structures were analyzed to classify the known supramolecular synthons for sulfonamides and named as the *anti* catemer, *syn* catemer, finite catemer; continuous dimers, alternative dimers (Fig. 7[▸](#fig7){ref-type="fig"} *b*), dimers making rings, finite dimers; tetramers, three point synthons, and finally a miscellaneous cluster of mixed motifs (Fig. 7[▸](#fig7){ref-type="fig"}, CSD refcodes are provided in [Table S2](#suppinfoanchor)). The presence of multiple donors/acceptors on the SO~2~NH~2~ group together with conformational flexibility (*syn*/*anti*) leads to many possible hydrogen bond synthons. In contrast, the *syn* amides are more predictable and show mainly dimer and to a lesser extent catemer synthons. The synthons in Fig. 7[▸](#fig7){ref-type="fig"}(*c*) suggest that the known heterosynthon between sulfonamide and N-oxide may be replaced by amide with the same graph set to provide a crystal engineering strategy for sulfonamide--carboxamide cocrystals.

A CSD search for the binary systems (cocrystals) furnished 33 hits for primary sulfonamides and 39 hits for secondary sulfonamides along with the starting materials of this study ([Fig. S5](#suppinfoanchor)). The almost equal numbers of primary and secondary sulfonamide cocrystals means that there are no steric issues with cocrystal assembly. Among the primary sulfonamide cocrystals, there are a few N---H⋯O hydrogen-bonded structures with amides, *e.g.* celecoxib-valerolactam trimorphs and nicotinamide cocrystals (see Fig. 7[▸](#fig7){ref-type="fig"}). Among the primary sulfonamide drugs, celecoxib, furosemide, acetazolamide and hydrochlorothiazide are notable for making cocrystals with amide coformers (Bolla *et al.*, 2014[@bb10]; Harriss *et al.*, 2014[@bb44]; Ueto *et al.*, 2012[@bb81]; Arenas-García *et al.*, 2010[@bb3]; Sanphui & Rajput, 2014[@bb67]; Remenar *et al.*, 2007[@bb65]), *e.g.* nicotinamide, isonicotinamide and picolinamide with different sulfonamide--amide syn­thons (see [Fig. S9](#supinfoanchor)).

There are 2046 sulfonamides in the CSD but only 72 binary systems (cocrystals) in the CSD. The fewer number of sulfonamide cocrystals compared to say those for carboxylic acids and amides could be due to the enthalpy penalty for disrupting the strong sulfonamide homosynthon in the parent crystal structures with an even stronger hydrogen bond in the cocrystal. The activated oxygen acceptor of N-oxides, and to a lesser extent carboxamide functional groups, has been successfully used for sulfonamide cocrystals. The present study presents a crystal engineering approach to sulfonamide--carboxamide cocrystals analogous to the sulfonamide--pyridine-N-oxide heterosynthon.

3.7.. Hirshfeld surface analysis   {#sec3.7}
----------------------------------

The Hirshfeld surface (using *Crystal Explorer*, Version 3.1, Hirshfeld, 1977[@bb45]; Hirshfeld & Mirsky, 1979[@bb46]; Kitaigorodsky, 1973[@bb50]; Vainshtein *et al.*, 1982[@bb83]; Spackman & Jayatilaka, 2009[@bb73], McKinnon *et al.*, 1998[@bb52]) translates the electron density into molecular fragments and also volume around a molecule in a manner similar to the van der Waals surface, or an outer surface of the electron density in a crystal structure. The Hirshfeld surface is related to the molecule and the proximity of its nearest neighbors and this allows easy identification of characteristic strong and weak interactions throughout the structure. It explains the nature of intermolecular interactions within a crystal structure using a two-dimensional fingerprint plot consisting of spikes and wings. The 4BrBSA--VLM cocrystal two-dimensional finger plots with all types of interactions are shown in Fig. 8[▸](#fig8){ref-type="fig"} as a representative of this class. The other binary systems are shown in [Fig. S6](#supinfoanchor). The strong spikes at 1.0--1.2 Å correspond to H⋯O interactions and the weak spikes between 1.2 and 1.4 Å for H⋯N hydrogen bonds. The other H⋯*X*, H⋯H, H⋯C interactions occur between 1.5 and 2.4 Å in the wings region. The strong H⋯O interaction is the major contributor in cocrystal structures ([Fig. S7 and Table S3](#supinfoanchor)).

4.. Conclusions   {#sec4}
=================

A crystal engineering strategy is described for cocrystals of an otherwise less studied but pharmaceutically very important class of sulfonamide functional group. The binary systems of benzene sulfonamide--lactam exhibit three types of heterosynthons. The N---H donor of the sulfonamide forms a hydrogen bond with the C=O acceptor in different arrangements to result in synthon 1 of the catemer chain, synthon 2 as a dimer--cyclic motif and synthon 3 as a dimer--catemer. The classification of cocrystal structures in these synthon categories now offers a design element for sulfa drug cocrystals with GRAS coformers. Interestingly, isostructural pairs of cocrystals with isosynthons are observed in this study, which not only facilitates classification but also correlates with known cocrystal structures in the CSD, *e.g.* the novel sulfonamide--amide synthon analogous to the reported sulfonamide--N-oxide. The cocrystals of primary sulfonamides with GRAS coformers will provide an entry to the modification of sulfa drugs *via* pharmaceutical cocrystals.

Supplementary Material
======================

Crystal structure: contains datablock(s) global, 2ABSACPR, BSAAZL, 4ClBSACPR, SNACPR, 4BrBSACPR, OTSAVLM, 2ClBSACPR, BSACPR, 4ClBSAVLM, 4BrBSAVLM, PTSAVLM, 2ClBSAVLM, BSAVLM. DOI: [10.1107/S2052252515004960/zx5004sup1.cif](http://dx.doi.org/10.1107/S2052252515004960/zx5004sup1.cif)

Structure factors: contains datablock(s) 2ABSACPR. DOI: [10.1107/S2052252515004960/zx50042ABSACPRsup2.hkl](http://dx.doi.org/10.1107/S2052252515004960/zx50042ABSACPRsup2.hkl)

Structure factors: contains datablock(s) BSAAZL. DOI: [10.1107/S2052252515004960/zx5004BSAAZLsup3.hkl](http://dx.doi.org/10.1107/S2052252515004960/zx5004BSAAZLsup3.hkl)

Structure factors: contains datablock(s) BSAVLM Structure factors: contains datablock(s) BSAVLM. DOI: [10.1107/S2052252515004960/zx5004BSAVLMsup14.hkl](http://dx.doi.org/10.1107/S2052252515004960/zx5004BSAVLMsup14.hkl)

Structure factors: contains datablock(s) SNACPR. DOI: [10.1107/S2052252515004960/zx5004SNACPRsup5.hkl](http://dx.doi.org/10.1107/S2052252515004960/zx5004SNACPRsup5.hkl)

Structure factors: contains datablock(s) 4BrBSACPR. DOI: [10.1107/S2052252515004960/zx50044BrBSACPRsup6.hkl](http://dx.doi.org/10.1107/S2052252515004960/zx50044BrBSACPRsup6.hkl)

Structure factors: contains datablock(s) OTSAVLM. DOI: [10.1107/S2052252515004960/zx5004OTSAVLMsup7.hkl](http://dx.doi.org/10.1107/S2052252515004960/zx5004OTSAVLMsup7.hkl)

Structure factors: contains datablock(s) 2ClBSACPR. DOI: [10.1107/S2052252515004960/zx50042ClBSACPRsup8.hkl](http://dx.doi.org/10.1107/S2052252515004960/zx50042ClBSACPRsup8.hkl)

Structure factors: contains datablock(s) BSACPR. DOI: [10.1107/S2052252515004960/zx5004BSACPRsup9.hkl](http://dx.doi.org/10.1107/S2052252515004960/zx5004BSACPRsup9.hkl)

Structure factors: contains datablock(s) 4ClBSAVLM. DOI: [10.1107/S2052252515004960/zx50044ClBSAVLMsup10.hkl](http://dx.doi.org/10.1107/S2052252515004960/zx50044ClBSAVLMsup10.hkl)

Structure factors: contains datablock(s) 4BrBSAVLM. DOI: [10.1107/S2052252515004960/zx50044BrBSAVLMsup11.hkl](http://dx.doi.org/10.1107/S2052252515004960/zx50044BrBSAVLMsup11.hkl)

Structure factors: contains datablock(s) PTSAVLM. DOI: [10.1107/S2052252515004960/zx5004PTSAVLMsup12.hkl](http://dx.doi.org/10.1107/S2052252515004960/zx5004PTSAVLMsup12.hkl)

Structure factors: contains datablock(s) 2ClBSAVLM. DOI: [10.1107/S2052252515004960/zx50042ClBSAVLMsup13.hkl](http://dx.doi.org/10.1107/S2052252515004960/zx50042ClBSAVLMsup13.hkl)

Structure factors: contains datablock(s) BSAVLM Structure factors: contains datablock(s) BSAVLM. DOI: [10.1107/S2052252515004960/zx5004BSAVLMsup14.hkl](http://dx.doi.org/10.1107/S2052252515004960/zx5004BSAVLMsup14.hkl)

Supporting tables and figures. DOI: [10.1107/S2052252515004960/zx5004sup15.pdf](http://dx.doi.org/10.1107/S2052252515004960/zx5004sup15.pdf)
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![(*a*) Synthons present in primary sulfonamides (homosynthons). (*b*) Synthon motifs present in sulfonamide cocrystals (heterosynthons) from the literature study. (*c*) Synthon motifs present in sulfonamide cocrystals discussed in this report (heterosynthons).](m-02-00389-fig1){#fig1}

![Molecular structure of the primary sulfonamides and lactams used in this study to make binary cocrystals.](m-02-00389-fig2){#fig2}

![Classification of three novel synthons in sulfonamide--lactam cocrystals. Names of the cocrystal structures are shown in the bottom row.](m-02-00389-fig3){#fig3}

###### 

Crystal structures of sulfonamide--lactam cocrystals with catemer synthon 1. Two-dimensional packing diagrams are drawn with the asymmetric unit showing benzene sulfonamides (in green) and lactams (in blue) (VLM, CPR).

![](m-02-00389-fig4a)

![](m-02-00389-fig4b)

![](m-02-00389-fig4c)

![Dimer--cyclic synthon 2 in cocrystals BSA--AZL, 2ABSA--CPR and two-dimensional layer packing. Two-dimensional packing diagrams are drawn with the asymmetric unit showing benzene sulfonamides (in green) and lactams (in blue) (VLM, CPR).](m-02-00389-fig5){#fig5}

###### 

Dimer--catemer synthon 3 in cocrystals 2ClBSA--VLM, 2ClBSA--CPR, OTSA--VLM, PTSA--VLM and two-dimensional hydrogen bond motifs. Two-dimensional packing diagrams are drawn with the asymmetric unit showing benzene sulfonamides (in green) and lactams (in blue) (VLM, CPR).

![](m-02-00389-fig6a)

![](m-02-00389-fig6b)

![(*a*) Classification of primary sulfonamide synthons reported in CSD and (*b*) their hydrogen bonding and frequency. (*c*) Synthons in cocrystals of primary sulfonamides with N-oxides and amides. The latter analysis suggests that sulfonamide--N-oxide synthons may be replaced by *syn*-amides to give a new strategy for sulfonamide--carboxamide cocrystals.](m-02-00389-fig7){#fig7}

![(*a*) Hirshfeld surfaces of the three types of the synthons present in sulfonamide--lactam cocrystals. (*b*) Two-dimensional fingerprint plots of the intermolecular contacts in the 4BrBSA--CPR cocrystal.](m-02-00389-fig8){#fig8}

###### Summary of characterization for sulfonamidelactam cocrystals

= yes, = no.

               VLM (six member lactam)   CPR (seven member lactam)             
  --- -------- ------------------------- --------------------------- --- -- -- ---
  1   BSA                                                                      
  2   OTSA                                                                      
  3   PTSA                                                                      
  4   SNA                                                                      
  5   2ABSA                                                                    
  6   2ClBSA                                                                   
  7   4ClBSA                                                                   
  8   4BrBSA                                                                   

###### Crystallographic data summary and classification of sulfonamidecarboxamide cocrystals and isostructurality (see Table 3[▸](#table3){ref-type="table"} for full crystallographic data)

  S. No.       Cocrystal   Cell parameters (*a*, *b*, *c*, in )   Crystal system                  Synthon observed
  ------------ ----------- -------------------------------------- ------------------------------- ------------------
  1            BSAVLM      *a* = 7                                Orthorhombic, *P*2~1~2~1~2~1~    
  2            BSACPR                                                                             
  3            4ClBSACPR   *b* = 1213                             Synthon 1                       
  4            4BrBSACPR   *c* = 1415                             Catemer chain                   
  5            SNACPR                                                                             
  6            4ClBSAVLM   *a* = 25                               Monoclinic, *C*2/*c*            
  7            4BrBSAVLM   *b* = 7                                                                
               *c* = 19                                                                           
  8            2ABSACPR    *a* = 7                                Monoclinic, *P*2~1~/*n*         Synthon 2
  9            BSAAZL      *b* = 1617                             DimerCyclic ring                
  *c* = 1213                                                                                      
  10           2ClBSAVLM   *a* = 910                              Monoclinic, *P*2~1~/*c*         Synthon 3
  11           2ClBSACPR   *b* = 1314                             DimerCatemer                    
  *c* = 10                                                                                        
  12           PTSAVLM     *a* = 5                                Monoclinic, *P*2~1~/*n*         
  *b* = 16                                                                                        
  *c* = 16                                                                                        
  13           OTSAVLM     *a* = 5                                Triclinic,                      
  *b* = 8                                                                                         
  *c* = 16                                                                                        

###### Crystallographic parameters of the sulfonamide cocrystals with lactams of this study

                              Catemer synthon                                                                                                                                                                
  --------------------------- -------------------------- --------------------------- ----------------------------- ----------------------------- ------------------------------ ---------------------------- ----------------------------
  Empirical formula           C~6~H~7~NO~2~SC~5~H~9~NO   C~6~H~7~NO~2~SC~6~H~11~NO   C~6~H~6~ClNO~2~SC~6~H~11~NO   C~6~H~6~BrNO~2~SC~6~H~11~NO   C~6~H~8~N~2~O~2~SC~6~H~11~NO   C~6~H~6~ClNO~2~SC~5~H~9~NO   C~6~H~6~BrNO~2~SC~5~H~9~NO
  Formula weight              256.33                     270.35                      304.80                        349.25                        285.37                         290.77                       335.22
  Crystal system              Orthorhombic               Orthorhombic                Orthorhombic                  Orthorhombic                  Orthorhombic                   Monoclinic                   Monoclinic
  Space group                 *P*2~1~2~1~2~1~            *P*2~1~2~1~2~1~             *P*2~1~2~1~2~1~               *P*2~1~2~1~2~1~               *P*2~1~2~1~2~1~                *C*2/*c*                     *C*2/*c*
  *T* (K)                     298(3)                     298(3)                      298(3)                        298(3)                        298(3)                         298(3)                       298(3)
  *a* ()                      7.1043(5)                  7.0700(9)                   7.1564(13)                    7.156(3)                      7.0957(6)                      25.701(4)                    25.914(3)
  *b* ()                      12.7937(10)                12.7624(13)                 13.369(2)                     13.538(5)                     13.1280(13)                    6.8096(4)                    6.8687(9)
  *c* ()                      14.0302(16)                14.977(2)                   15.276(3)                     15.406(6)                     15.3425(18)                    19.177(3)                    19.202(2)
  ()                          90                         90                          90                            90                            90                             90                           90
  ()                          90                         90                          90                            90                            90                             127.40(2)                    126.873(2)
  ()                          90                         90                          90                            90                            90                             90                           90
  *V* (^3^)                   1275.2(2)                  1351.4(3)                   1461.5(4)                     1492.5(10)                    1429.2(3)                      2666.2(9)                    2734.2(6)
  *D* ~calc~ (gcm^3^)         1.335                      1.329                       1.385                         1.554                         1.326                          1.449                        1.629
  (mm^1^)                     0.253                      0.242                       0.409                         2.899                         0.235                          0.445                        3.161
  range                       3.5927.83                  3.9626.72                   2.8426.31                     2.0026.38                     2.6424.65                      2.6626.31                    1.9626.35
  *Z*/*Z* ^1^                 4/1                        4/1                         4/1                           4/1                           4/1                            8/1                          8/1
  *h* range                   4 +8                       8 +7                        8 +7                          8 +8                          7 +8                           32 +30                       32 +32
  *k* range                   15 +15                     7 +15                       12 +16                        16 +16                        8 + 15                         8 +8                         8 +8
  *l* range                   17 12                      17 +16                      12 +19                        19 +19                        18 15                          23 +22                       23 +23
  Reflections collected       3791                       3348                        4403                          15786                         3692                           5127                         14029
  Total reflections           2493                       2197                        2851                          3029                          2354                           2732                         2790
  Observed reflections        2175                       1595                        1152                          2405                          1318                           1677                         2216
  *R* ~1~ \[*I* \> 2(*I*)\]   0.0466                     0.0777                      0.0896                        0.0398                        0.0529                         0.0595                       0.0348
  *wR* ~2~ (all)              0.1201                     0.1806                      0.1141                        0.0931                        0.0796                         0.1344                       0.0939
  Goodness-of-fit             1.059                      1.231                       0.968                         1.025                         0.901                          1.067                        1.029
  X-ray diffractmeter         Oxford Gemini              Oxford Gemini               Oxford Gemini                 Bruker Smart Apex             Oxford Gemini                  Oxford Gemini                Bruker Smart Apex

                              Dimercyclic synthon ring       Dimercatemer synthon                                                                                               
  --------------------------- ------------------------------ --------------------------- ---------------------------- ----------------------------- --------------------------- ---------------------------
  Empirical formula           C~6~H~8~N~2~O~2~SC~6~H~11~NO   C~6~H~7~NO~2~SC~7~H~13~NO   C~6~H~6~ClNO~2~SC~5~H~9~NO   C~6~H~6~ClNO~2~SC~6~H~11~NO   C~7~H~9~NO~2~SC~5~ H~9~NO   C~7~H~9~NO~2~SC~5~ H~9~NO
  Formula weight              285.37                         284.36                      290.77                       304.80                        270.35                      270.35
  Crystal system              Monoclinic                     Monoclinic                  Monoclinic                   Monoclinic                    Monoclinic                  Triclinic
  Space group                 *P*2~1~/*n*                    *P*2~1~/*n*                 *P*2~1~/*c*                  *P*2~1~/*c*                   *P*2~1~/*n*                 *P-*1
  *T* (K)                     29(3)                          298(3)                      298(3)                       298(3)                        298(3)                      298(3)
  *a* ()                      7.2731(4)                      7.3020(9)                   10.521(2)                    9.8782(6)                     5.3367(6)                   5.210(3)
  *b* ()                      15.9052(10)                    17.189(2)                   13.7661(12)                  14.1720(6)                    15.9206(17)                 8.449(4)
  *c* ()                      12.7766(6)                     12.2835(16)                 10.3407(16)                  10.8753(6)                    16.070(3)                   16.104(8)
  ()                          90                             90                          90                           90                            90                          82.894(8)
  ()                          99.291(5)                      106.760(2)                  116.31(2)                    112.850(7)                    98.308(12)                  82.798(8)
  ()                          90                             90                          90                           90                            90                          81.772(8)
  *V* (^3^)                   1458.61(14)                    1476.3(3)                   1342.5(4)                    1403.00(15)                   1351.0                      692.005
  *D* ~calc~ (gcm^3^)         1.299                          1.280                       1.439                        1.443                         1.329                       1.298
  (mm^1^)                     0.230                          0.225                       0.442                        0.426                         0.242                       0.236
  range                       3.1228.72                      2.9323.26                   2.7326.37                    2.8726.37                     2.562.56                    1.2826.37
  *Z*/*Z* ^1^                 4/1                            4/1                         4/1                          4/1                           4/1                         2/1
  *h* range                   8 +8                           8 +8                        12 +13                       12 +11                        6 +6                        6 +6
  *k* range                   16 +18                         20 +20                      15 +17                       17 +16                        19 +11                      10 +10
  *l* range                   15 +14                         14 +14                      11 +12                       13 + 10                       14 +20                      20 +19
  Reflections collected       5525                           13710                       5058                         5810                          5072                        7341
  Total reflections           2488                           2520                        2731                         2870                          2759                        2819
  Observed reflections        1993                           2154                        2039                         2483                          1420                        1969
  *R* ~1~ \[*I* \> 2(*I*)\]   0.0383                         0.0597                      0.0435                       0.0385                        0.0645                      0.0504
  *wR* ~2~ (all)              0.0995                         0.1419                      0.1144                       0.1031                        0.1183                      0.1526
  Goodness-of-fit             1.017                          1.092                       0.983                        1.093                         1.019                       1.043
  X-ray diffractmeter         Oxford Gemini                  Bruker Smart Apex           Oxford Gemini                Oxford Gemini                 Oxford Gemini               Bruker Smart Apex

###### Unit-cell similarity index () of cocrystals

  Cocrystal[†](#tfn2){ref-type="table-fn"}   Crystal system/space group      Cell values               Cell values summation        
  ------------------------------------------ ------------------------------- ------------------------- ---------------------------- --------
  BSAVLM^*a*^                                Orthorhombic, *P*2~1~2~1~2~1~   7.104, 12.793, 14.030     33.928                       0.0253
  BSACPR^*a*^                                7.070, 12.762, 14.977           34.809                                                 
  4ClBSACPR^*a*^                             7.156, 13.369, 15.276           35.801                    0.0082                       
  4BrBSACPR^*a*^                             7.156, 13.538, 15.406           36.100                                                 
  SNACPR^*a*^                                7.095, 13.128, 15.342           35.566                    0.0147 (SNACPR, 4BrBSACPR)   
  4ClBSAVLM^*b*^                             Monoclinic, *C*2/*c*            25.701, 6.809, 19.177     51.900                       0.0016
  4BrBSAVLM^*b*^                             25.914, 6.8687, 19.202          51.984                                                 
  2ClBSAVLM^*c*^                             Monoclinic, *P*2~1~/*c*         10.521, 13.7661, 10.340   34.627                       0.0085
  2ClBSACPR^*c*^                             9.878, 14.172, 10.875           34.925                                                 
  2ABSACPR^*d*^                              7.273, 15.905, 12.776           35.954                    0.0223                       
  BSAAZL^*d*^                                7.302, 17.189, 12.2835          36.774                                                 

*a*, *b*, *c*, *d* are the different isomorphous systems as detailed in Table 1[▸](#table1){ref-type="table"}.

###### CSD data on sulfonamides and their cocrystals

Hydrates, solvates, salts and duplicates were removed in counting statistics.

  Sulfonamides                                        CSD hits
  --------------------------------------------------- ----------
  No. of primary sulfonamides reported                220
  No. of secondary sulfonamides reported              2160
  No. of primary sulfonamides cocrystals reported     33
  No. of secondary sulfonamides cocrystals reported   39
